Rapid Synthesis of Plasmids and Mutagensis for CVV Research

ID: PR79011 • Type: Solicitation

Description

Posted: Aug. 11, 2023, 10:18 a.m. EDT

8/11/2023 - Update - Extend the due date to 8/21/2023 and upload the answers to the questions. See attachment for Q&A.

8/3/2023- Update- This solicitation has been extended to 8/17. Questions are due 8/10/2023, noon EST.

As part of Centers for Disease Control and Prevention's (CDC's) mission of influenza pandemic preparedness and response, the Influenza Division (ID) develops and delivers medical countermeasures. One such medical countermeasure are candidate vaccine viruses (CVVs), which are precursor vaccine products or seeds developed by partners within the World Health Organization (WHO) Global Influenza Surveillance and Responses System (GISRS). GISRS monitors human influenza disease burden, monitors antigenic drift and other changes (such as antiviral drug resistance) in seasonal influenza viruses, obtains suitable virus isolates for updating of influenza vaccines, and detects and obtains isolates of new influenza viruses infecting humans, especially those with pandemic potential to be use for research and vaccine development.

To facilitate the development of the CVVs, CDC uses oligonucleotides and synthetic genes to transcribe the influenza genes to produce the CVVs. ID requires plasmids and linear DNA to be developed routinely based on the constant changes in the genetic make-up of the circulating and novel viruses. These changes are unpredictable and cannot be identified until the viruses are isolated from patients or infected animals. Further, the synthesis of genes is often the rate limiting step in rapid reverse genetics (RG) CVV production, which is required to meet vaccine preparedness goals.

Inquiries should be received at the Contracting Office no later than 21 July 2023, submitted via e-mail. See Section 4 (Inquiries) for specific instructions.

Posted: Aug. 3, 2023, 8:29 a.m. EDT

Posted: July 18, 2023, 5:54 a.m. EDT

Background
As part of Centers for Disease Control and Prevention's (CDC's) mission of influenza pandemic preparedness and response, the Influenza Division (ID) develops and delivers medical countermeasures. One such medical countermeasure are candidate vaccine viruses (CVVs), which are precursor vaccine products or seeds developed by partners within the World Health Organization (WHO) Global Influenza Surveillance and Responses System (GISRS). GISRS monitors human influenza disease burden, monitors antigenic drift and other changes in seasonal influenza viruses, obtains suitable virus isolates for updating of influenza vaccines, and detects and obtains isolates of new influenza viruses infecting humans, especially those with pandemic potential to be used for research and vaccine development.

Work Details
The contract requires the rapid synthesis of plasmids and mutagenesis for CVV research. The contractor shall provide linear DNA fragments of up to 2,000 base pairs (bp) in length with an error rate less than 1bp per 5,000bp. The turnaround time (TAT) will be less than four (4) business days and expected minimum yield of 1μg.

Additionally, purified plasmid DNA preparations with an insert length of up to 2,000bp in length with an error rate less than 1bp per 5,000bp are required with a TAT of less than five (5) business days and expected minimum yield of 5μg.

Furthermore, purified plasmid DNA preparations with an insert length of up to 4,000bp in length with an error rate less than 1bp per 5,000bp are needed with a TAT of less than six (6) business days and expected minimum yield of 5μg.

Period of Performance
The base period for the contract is from 07/10/2023 to 07/09/2024. There are also option years from 07/10/2024 to 07/09/2025, from 07/10/2025 to 07/09/2026, and from 07/10/2026 to 07/09/2027.

Place of Performance
The products will be delivered to CDC Distribution Center (Warehouse), located at 3719 North Peachtree Rd., Chamblee, Georgia, 30341-2221, United States.

Overview

Agency

Centers for Disease Control and Prevention (CDC) [HHS]

Response Deadline

Aug. 21, 2023, 4:00 p.m. EDT (original: Aug. 2, 2023, 4:00 p.m. EDT) Past Due

Posted

July 18, 2023, 5:54 a.m. EDT (updated: Aug. 11, 2023, 10:18 a.m. EDT)

Set Aside

None

NAICS

541380 - Testing Laboratories and Services

PSC

6640 - Laboratory Equipment And Supplies

Place of Performance

Atlanta, GA 30333 United States

Source

SAM

Current SBA Size Standard

$19 Million

Est. Level of Competition

Average

On 7/18/23 Centers for Disease Control and Prevention issued Solicitation PR79011 for Rapid Synthesis of Plasmids and Mutagensis for CVV Research due 8/21/23. The opportunity was issued full & open with NAICS 541380 and PSC 6640.

Primary Contact

Name

Castrinos, Nicholas Profile

ugn8@cdc.gov

Phone

(804) 661-1410

Question & Answer

Incumbent or Similar Awards

Potential Bidders and Partners

Awardees that have won contracts similar to Solicitation PR79011

Additional Details

Source Agency Hierarchy

HEALTH AND HUMAN SERVICES, DEPARTMENT OF > CENTERS FOR DISEASE CONTROL AND PREVENTION > CDC OFFICE OF ACQUISITION SERVICES

FPDS Organization Code

7523-00254

Source Organization Code

100188028

Last Updated

Sept. 30, 2023

Last Updated By

krz3@cdc.gov

Archive Date